Figure 3.

Effect of anti-TNF treatment on peripheral blood B cells in rheumatoid arthritis patients. (a) No effect of anti-TNF treatment on peripheral blood (PB) CD19⁺ cells, CD19⁺HLA-DR⁺ cells, and CD19⁺CD27⁺ cells in rheumatoid arthritis (RA) patients (n = 7). B-cell depletion is specific to rituximab therapy. (b) Treatment with rituximab does not affect the proportion of total CD4⁺ T cells, activated CD4⁺HLA-DR⁺ T cells and CD4⁺CD25⁺ T cells in the PB of RA patients.